Have you been eager to see how The Charles Schwab Corporation (SCHW - Free Report) performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this San Francisco-based brokerage company’s earnings release this morning:
An Earnings Beat
Schwab came out with earnings per share of 42 cents, beating the Zacks Consensus Estimate of 41 cents.
Results benefited from improved revenues.
How Was the Estimate Revision Trend?
You should note that the earnings estimate revisions for Schwab depicted a neutral stance prior to the earnings release. The Zacks Consensus Estimate has remained stable over the last 7 days.
However, Schwab has delivered positive surprises in two of the prior four trailing quarters. Overall, the company has a positive earnings surprise of 2.1% in the trailing four quarters.
Schwab posted net revenues of $2.17 billion, which lagged the Zacks Consensus Estimate of$2.19 billion. However, it compared favorably with the year-ago number of $1.91 billion.
- A steady focus on serving investor needs has helped Schwab’s business grow to $3.18 trillion in client assets as of Sep 30, 2017
- Core net new assets of $51.6 billion as of Sep 30, 2017, up 72% year over year
- Increase in average interest-earning assets by 10% to $214.3 billion at the end of the reported quarter
- Fee waivers declined to $1 million from $41 million in the prior year quarter.
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Schwab. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Check back later for our full write up on this Schwab earnings report!
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>